Sodium Acetate Shows Mixed Results in Kidney Injury Study
A retrospective analysis of robotic partial nephrectomy patients found sodium acetate did not lower overall acute kidney injury rates.
Updated on Nov. 20, 2026 in Cancer

Sodium acetate did not reduce the overall risk of acute kidney injury after robotic partial nephrectomy in a retrospective analysis of 263 patients treated between 2023 and 2025. Possible benefit appeared in moderate-risk and high-risk patients, according to findings presented at IKCS: North America 2026.
Why it matters
Partial nephrectomy is a common surgery for kidney tumors, and kidney injury after the procedure can affect long-term kidney function. The results suggest that any protective effect of sodium acetate may depend on a patient's baseline risk, which could shape how the drug is used in future surgeries.
The retrospective analysis compared 144 patients given sodium acetate with 119 who were not, finding AKI in 13.2% versus 16.6%, with observed-to-expected ratios of 1.48 and 1.66. The benefit in moderate-risk patients (13% versus 20%) and high-risk patients (25% versus 28.6%) has not been confirmed in a prospective trial.
The details
Researchers reviewed records of patients who underwent robotic-assisted partial nephrectomy and compared those who received intraoperative sodium acetate, administered from induction of anesthesia to robot undocking, with those who did not. Acute kidney injury within 14 days was defined using peak serum creatinine under RIFLE criteria. Low-risk patients showed no benefit from the drug.
Timeline
Patients in the study underwent robotic-assisted partial nephrectomy between 2023 and 2025.
Findings were presented at IKCS: North America 2026 in Dallas, November 19-21, 2026.
Health Landscape
Acute kidney injury after partial nephrectomy has been measured using the RIFLE criteria, which this study applies to test whether sodium acetate can reduce the complication. The findings add to ongoing efforts to tailor kidney-protection strategies to individual patient risk levels in tumor surgery.
For patients facing partial nephrectomy, the findings suggest that discussing kidney-protection options with a surgeon may be more useful when baseline risk is moderate or high. Low-risk patients did not show a benefit, so the drug is not indicated for everyone.
The takeaway
Sodium acetate did not lower overall kidney injury risk in this study, but moderate- and high-risk patients may benefit, and prospective trials are needed to confirm this.
Further reading
Explore more on Cancer treatment and surgical outcomes.
Source note: This article includes information reported by Cancer Therapy Advisor.






